Rimonabant

A pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and maturation of ADIPOCYTES, improves lipid and glucose metabolism, and regulates food intake and energy balance. It is used in the management of OBESITY.

Also Known As:

Acomplia; N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride; Rimonabant Hydrochloride; SR 141716; SR 141716A; SR-141716A; SR141716; SR141716A; Zimulti; 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-

Networked: 801 relevant articles (110 outcomes, 178 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - Rimonabant: 801
  - Piperidines: 17
    - Rimonabant: 801

Experts

1.	Bifulco, Maurizio: 12 articles (01/2017 - 10/2004)
2.	Makriyannis, Alexandros: 10 articles (03/2019 - 02/2004)
3.	Després, Jean-Pierre: 10 articles (07/2011 - 11/2005)
4.	Kim, Jeongmin: 10 articles (02/2010 - 04/2008)
5.	Lee, Jinhwa: 10 articles (02/2010 - 04/2008)
6.	Lee, Sung-Han: 10 articles (02/2010 - 04/2008)
7.	Gazzerro, Patrizia: 9 articles (01/2017 - 10/2006)
8.	Laezza, Chiara: 9 articles (01/2017 - 10/2004)
9.	Di Marzo, Vincenzo: 9 articles (11/2013 - 12/2002)
10.	Seo, Hee Jeong: 9 articles (02/2010 - 04/2008)

Related Diseases

1.	Obesity 04/01/2008 - "However, given the efficacy of this treatment and the magnitude of the obesity problem, rimonabant may prove to be a valuable adjunct in targeting obesity-related cardiovascular risk factors." 06/01/2017 - "Past information generated on the ECS, mainly focused on the involvement of this system in the central nervous system regulation of food intake, while at the same time clinical studies pointed out the therapeutic efficacy of brain penetrant CB1R antagonists like rimonabant for obesity and metabolic disorders. " 01/01/2020 - "Although the first-in-class CB1R antagonist rimonabant proved to be effective in mitigating obesity and its multiple cardiometabolic complications, it was withdrawn from clinical use due to CNS-mediated neuropsychiatric side effects, which halted the further therapeutic development of the whole class of these compounds. " 05/01/2012 - "They have been explored and found to be effective as therapeutic agents for obesity and related cardiometabolic problems; however, use of rimonabant, the first marketed CB(1) receptor antagonist, has been suspended because of its anxiogenic and depressogenic side effects. " 04/01/2005 - "In humans, rimonabant appears to be effective for treatment of obesity and smoking cessation. "
2.	Weight Loss (Weight Reduction) 01/01/2014 - "Central CB1R antagonists, notably rimonabant, induced weight loss and improved the metabolic profile in obese individuals, but were discontinued due to psychiatric side-effects. " 10/01/2009 - "Rimonabant resulted in a significantly greater benefit than placebo for all primary weight loss outcomes. " 07/01/2008 - "Weight loss from baseline to 2 years in the intention-to-treat population was significantly greater with rimonabant 20 mg (mean +/- SD: -5.5 +/- 7.7 kg; P < 0.001) and 5 mg (-2.9 +/- 6.5 kg; P = 0.002) than placebo (-1.2 +/- 6.8 kg). " 11/11/2006 - "Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: -1.4 kg [SD 3.6]; 5 mg/day: -2.3 kg [4.2], p=0.01 vs placebo; 20 mg/day: -5.3 kg [5.2], p<0.0001 vs placebo). " 01/01/2006 - "A significantly greater proportion of rimonabant than placebo recipients achieved the clinically significant weight-loss target of > or =5% or > or =10% of initial weight. "
3.	Insulin Resistance 07/01/2013 - "Irrespective of its psychiatric side effects, rimonabant through blocking cannabinoid-1 receptor (CB1R) induces an increase in whole body insulin sensitivity. " 08/01/2009 - "Conversely, a single dose of rimonabant to DIO rats had no acute effect on insulin sensitivity. " 01/16/2009 - "Interestingly, the rimonabant-treated adipo(-/-)ob/ob mice also exhibited significant amelioration of insulin resistance, although the degree of improvement was significantly lower as compared with that in the ob/ob mice. " 01/01/2019 - "It was as effective as rimonabant for the improvement of hormonal or metabolic abnormalities, glycemic control, and insulin sensitivity. " 12/01/2011 - "Our findings suggest that SR141716 can improve liver lipid metabolism in foz/foz mice in line with improved insulin sensitivity and adipose tissue inflammation."
4.	Body Weight (Weight, Body) 02/01/2013 - "These results provide proof of principle that combination of rimonabant and a MCH1 receptor antagonist is highly effective in reducing body weight below that achieved by rimonabant and SNAP-94847 monotherapies. " 02/01/2013 - "Combining sub-threshold doses of rimonabant and SNAP-94847 produced a significantly greater loss of body weight in DIO mice compared with vehicle and monotherapies. " 02/01/2010 - "On all three diets, rimonabant treatment improved metabolic derangements and led to significantly lower body weight gain than their respective controls. " 01/01/2018 - "Our study demonstrated that SR141716A accelerated the clinical onset and development of EAE, accompanied by body weight loss. " 02/01/2011 - "In all the trials, there was a considerable reduction in body weight in subjects taking 20 mg rimonabant daily varying from 2.6 to 6.3 kg (placebo-subtracted changes). "
5.	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/01/2010 - "Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome." 07/01/2013 - "Rimonabant also has cardioprotective actions in rats characterised by the metabolic syndrome. " 07/01/2008 - "Rimonabant in rats with a metabolic syndrome: good news after the depression." 05/01/2007 - "Rimonabant may be a useful adjunct to lifestyle and behavior modification in the treatment of obese subjects with metabolic syndrome or multiple cardiometabolic risk factors." 03/01/2007 - "The frequency of metabolic syndrome also decreased significantly with rimonabant 20 mg daily. "

Related Drugs and Biologics

1.	CB1 Cannabinoid Receptor (CB1 Receptor)
2.	Glucose (Dextrose)
3.	Triglycerides (Triacylglycerol)
4.	Cannabinoids
5.	Lipids
6.	Rimonabant
7.	HDL Cholesterol
8.	Endocannabinoids
9.	Insulin (Novolin)
10.	Cholesterol

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Drug Therapy (Chemotherapy)
4.	Ligation
5.	Tobacco Use Cessation Devices